Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study

Authors

B. Besse
M. Johnson
S. H. I. Ou
Shirish M. Gadgeel, Henry Ford HealthFollow
A. Spira
J. Lin
E. Felip
A. J. van der Wekken
A. Calles
M. J. de Miguel
D. R. Camidge
Y. Elamin
G. D. L. Lopes
S. Liu
J. Bauman
D. Haggstrom
G. Riley
H. E. Pelish
V. W. Zhu
A. Drilon

Recommended Citation

Besse B, Johnson M, Ou SHI, Gadgeel S, Spira A, Lin J, Felip E, van der Wekken AJ, Calles A, de Miguel MJ, Camidge DR, Elamin Y, Lopes GDL, Liu S, Bauman J, Haggstrom D, Riley G, Pelish HE, Zhu VW, and Drilon A. Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study. Ann Oncol 2022; 33:S68-S69.

Document Type

Conference Proceeding

Publication Date

4-1-2022

Publication Title

Ann Oncol

Volume

33

First Page

S68

Last Page

S69